Evidence map›Paper›PMID 29659591›Full record

ArticlePloS one2018

Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.

Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Yukio Osaki, Yuji Kojima, Ryo Nakata, Tohru Goto, Akahane Takehiro, Hiroyuki Kimura and 15 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. [Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: a 2021 update].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 18 institutions in 1 country.

Toshie MashibaCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Ehime, Japan.
Kouji JokoCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Ehime, Japan.ORCID 0000-0001-8111-3266
Masayuki KurosakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Hironori OchiCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Ehime, Japan.
Yukio OsakiDepartment of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
Yuji KojimaDepartment of Hepatology, Japanese Red Cross Ise Hospital, Mie, Japan.
Ryo NakataDepartment of Gastroenterology, Japanese Red Cross Medical Center, Tokyo, Japan.
Tohru GotoDepartment of Gastroenterology, Omori Red Cross Hospital, Tokyo, Japan.
Akahane TakehiroDepartment of Gastroenterology, Ishinomaki Red Cross Hospital, Miyagi, Japan.
Hiroyuki KimuraDepartment of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Akeri MitsudaDepartment of Internal Medicine, Japanese Red Cross Tottori Hospital, Tottori, Japan.
Chiharu KawanamiDepartment of Gastroenterology, Otsu Red Cross Hospital, Shiga, Japan.
Yasushi UchidaDepartment of Gastroenterology, Matsue Red Cross Hospital, Shimane, Japan.
Chikara OgawaDepartment of Gastroenterology, Takamatsu Red Cross Hospital, Kagawa, Japan.
Atsunori KusakabeDepartment of Gastroenterology, Japanese Red Cross Nagoya Daini Hospital, Aichi, Japan.
Ryuichi NaritaDepartment of Gastroenterology, Oita Red Cross Hospital, Oita, Japan.
Yasushi IdeDepartment of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
Takehiko AbeDepartment of Gastroenterology, Maebashi Red Cross Hospital, Gunma, Japan.
Keiji TsujiDepartment of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Tadashi KitamuraDepartment of Gastroenterology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
Kazuhiko OkadaDepartment of Gastroenterology, Toyama Red Cross Hospital, Toyama, Japan.
Tetsuro SohdaHepatology Division, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Masaya ShigenoDepartment of Gastroenterology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Takashi SatouDepartment of Gastroenterology, Nasu Red Cross Hospital, Tochigi, Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Matsuyama Red Cross Hospital · JPMusashino Red Cross Hospital · JPTakamatsu Red Cross Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPIse Red Cross Hospital · JPJapanese Red Cross Fukuoka Hospital · JPJapanese Red Cross Medical Center · JPJapanese Red Cross Nagoya Daini Hospital · JPJapanese Red Cross Society, Japan · JPKyoto first Red Cross hospital · JPMaebashi Red Cross Hospital · JPMatsue Red Cross Hospital · JPOita Red Cross Hospital · JPOsaka Red Cross Hospital · JPOtsu Red Cross Hospital · JPShizuoka Red Cross Hospital · JPTottori Prefectural Central Hospital · JPYamaguchi Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimThis study aimed to elucidate whether interferon (IFN)-free direct-acting antiviral (DAA) therapy for hepatitis C after curative treatment of hepatocellular carcinoma (HCC) promotes HCC recurrence in a real-world large-scale cohort.

methodsThis multicenter study was conducted by the Japanese Red Cross Hospital Liver Study Group. This retrospective study analyzed 516 patients who underwent antiviral treatment for hepatitis C with either IFN (n = 148) or IFN-free DAA (n = 368) after curative HCC treatment; 78 IFN-treated patients and 347 IFN-free DAA-treated patients achieved sustained virological response (SVR). The recurrence rate of HCC was compared between the antiviral therapies. Logistic analysis and Cox proportional hazards analysis identified factors associated with early recurrence of HCC within 24 weeks of antiviral therapy and recurrence throughout the observation period, respectively.

resultsAFP at the completion of antiviral therapy, clinical stage of HCC, and non-SVR were independent factors associated with early recurrence of HCC. Among patients who had achieved SVR, the clinical stage of HCC and the level of AFP at completion of antiviral therapy were independent factors associated with early recurrence of HCC. For recurrence throughout the observation period in SVR patients, AFP at completion of antiviral therapy, duration between last HCC treatment to antiviral therapy, and the number of treatments were independent factors. There was no significant difference in the rate of early recurrence of HCC or recurrence throughout the observation period between IFN and IFN-free DAA treated patients.

conclusionsThere were no differences in the early recurrence rate of HCC between patients who underwent IFN and those who underwent IFN-free DAA as antiviral therapies.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsAntiviral AgentsArea Under CurveCarcinoma, HepatocellularFemaleHepatitis CHumansInterferonsLiver NeoplasmsLogistic ModelsMaleMiddle AgedNeoplasm Recurrence, LocalAntineoplastic AgentsAntiviral AgentsInterferons

Identifiers

PMID29659591
PMCPMC5901785
OpenAlexW2799499011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.